Skip to main content
. Author manuscript; available in PMC: 2021 May 5.
Published in final edited form as: Science. 2020 May 1;368(6490):eaau5480. doi: 10.1126/science.aau5480

Fig. 4. Evolution of AMPs and origin of AMPs as drugs.

Fig. 4.

(A) The number of AMPs currently undergoing clinical trials [data are from (4)] and the organisms from which they are derived. (B) Relative representation of animal taxa in the antimicrobial peptide database (5). This representation is not correlated with the number of species in each of the groups because, for example, insects are by far the most species-rich taxon.